Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 685

Results For "ED"

11158 News Found

Cresset opens new new India HQ in Bengaluru to tap potential of APAC market
News | May 17, 2024

Cresset opens new new India HQ in Bengaluru to tap potential of APAC market

Cresset’s new India site will support the growing demands of Cresset’s APAC customer base


Cipla invests additional Rs. 26 crore in Achira
News | May 16, 2024

Cipla invests additional Rs. 26 crore in Achira

Achira is engaged in development and commercialization of PoC medical test kits in India


Gujarat Themis Biosyn posts Q4 FY24 PAT at Rs. 15.88 Cr
News | May 15, 2024

Gujarat Themis Biosyn posts Q4 FY24 PAT at Rs. 15.88 Cr

The company has posted net profit of Rs. 59.16 crores for the Financial Year ended March 31, 2024


Merck discontinues Phase 3 KeyVibe-010 trial of coformulation of Vibostolimab and Pembrolizumab
Clinical Trials | May 14, 2024

Merck discontinues Phase 3 KeyVibe-010 trial of coformulation of Vibostolimab and Pembrolizumab

Data showed that the primary endpoint of recurrence-free survival (RFS) met the pre-specified futility criteria


Moderna update on investigational RSV vaccine
Drug Approval | May 14, 2024

Moderna update on investigational RSV vaccine

U.S. FDA has informed Moderna that due to administrative constraints, the agency will not complete its review of mRNA-1345 by the PDUFA date of May 12, 2024


Coveris invests over €8 million in production capacity
Packaging | May 14, 2024

Coveris invests over €8 million in production capacity

Investing considerably in production capacity for medical device packaging at its Rohrdorf and Halle sites in Germany


Sanofi India posts Q1 CY24 PAT at Rs. 136.6 Cr
News | May 14, 2024

Sanofi India posts Q1 CY24 PAT at Rs. 136.6 Cr

Sanofi India has reported total income of Rs. 738.9 crores during the period ended March 31, 2024


AbbVie and Gilgamesh Pharmaceuticals collaborate to develop next-gen therapies for psychiatric disorders
News | May 14, 2024

AbbVie and Gilgamesh Pharmaceuticals collaborate to develop next-gen therapies for psychiatric disorders

Collaboration to leverage AbbVie's psychiatry expertise and Gilgamesh's innovative research platform to develop next-generation neuroplastogens for the treatment of psychiatric disorders


Lonza reports softer performance in Q1 2024
News | May 14, 2024

Lonza reports softer performance in Q1 2024

Outlook 2024 remains flat CER sales growth and CORE EBITDA margin of high 20s


Bayer Q1 2024 net income drops 8.2% to € 2 billion
News | May 14, 2024

Bayer Q1 2024 net income drops 8.2% to € 2 billion

EBITDA before special items falls 1.3 percent to € 4.41 billion